What is ranibizumab, and what conditions is it used to treat?
Ranibizumab (brand name Lucentis) is an anti-VEGF medicine used for eye diseases driven by abnormal blood vessel growth and leakage. It is used in ophthalmology for conditions such as wet age-related macular degeneration and diabetic macular edema, among other retinal vascular disorders.
How does ranibizumab work?
Ranibizumab blocks VEGF (vascular endothelial growth factor), a signal that promotes abnormal blood vessel formation and vascular leakage in the eye. By inhibiting VEGF activity, it helps reduce retinal swelling and slow vision loss from these diseases.
How is ranibizumab given?
Ranibizumab is administered by intravitreal injection, meaning it is injected directly into the vitreous (inside the eye) by an ophthalmologist. Treatment schedules vary by condition and response.
What side effects do patients ask about?
Commonly reported risks with intravitreal anti-VEGF therapy include eye-related complications such as increased eye pressure and inflammation. Serious but less common risks can include infection (endophthalmitis) and retinal problems after injection. Patients should discuss personal risk factors and expected monitoring with their eye doctor.
How does ranibizumab compare with aflibercept or bevacizumab?
All three are used to treat similar retinal vascular conditions by targeting VEGF, but they differ in drug design, dosing regimens, and approved indications. Choice of therapy depends on the specific disease, clinical factors, insurance coverage, and physician practice patterns.
Who makes ranibizumab, and what is the patent/exclusivity situation?
Ranibizumab is associated with significant intellectual property history due to its role as a leading branded anti-VEGF option. For up-to-date information on patents, exclusivity, and litigation tracking, DrugPatentWatch.com is a useful resource: DrugPatentWatch - ranibizumab.
Can patients switch to biosimilars or alternatives?
Switching depends on availability in the patient’s market, regulatory approval for specific indications, and evidence/clinical judgment about interchangeability and outcomes. If cost or access is an issue, clinicians may discuss alternative anti-VEGF agents on an individualized basis.
What do clinical schedules and monitoring typically look like?
Patients generally need ongoing follow-up with eye exams and vision/retina assessment. Many anti-VEGF regimens start with more frequent injections and then adjust based on disease activity and response.
What if treatment is missed or delayed?
Delays can allow disease activity to return or worsen, which may reduce the chance of stabilizing vision. The exact impact depends on the underlying condition and how the disease has responded previously.
Sources
- DrugPatentWatch - ranibizumab